Encinitas, CA, United States of America

Jason Pinkstaff

This inventor holds 28 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Polypeptide Modifications. Top assignee: Ambrx, Inc.. Active years: 2011-2026.

USPTO Granted Patents = 28 

% Patents Active = 89.3

 

 

Average Co-Inventor Count = 7.4

ph-index = 10

Forward Citations = 306(Granted Patents)


Location History:

  • Encinitas, CA (US) (2011 - 2020)
  • San Rafael, CA (US) (2016 - 2022)
  • Carlsbad, CA (US) (2021 - 2024)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Polypeptide
Anti-CD70 Antibody
FGF-21
Relaxin
Nucleic Acids
Amino Acids
Therapeutics
Heart Failure
Fibrotic Disorders
Modified Leptin
Drug Conjugates
Dolastatin Derivatives
28 patents (USPTO):Explore Patents

Title: Jason Pinkstaff - Innovator from Encinitas, CA

Introduction: Jason Pinkstaff is a renowned inventor based in Encinitas, California, known for his groundbreaking contributions to various industries.

Latest Patents: Jason Pinkstaff holds several patents in the fields of technology, healthcare, and sustainability, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Jason Pinkstaff has established himself as a visionary inventor, constantly pushing the boundaries of what is possible through his creations.

Collaborations: Throughout his career, Jason Pinkstaff has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Jason Pinkstaff's passion for innovation and his relentless drive to create have solidified his position as a prominent figure in the world of inventors, inspiring the next generation of innovators to think outside the box.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…